Press Release
Aug 12 2024
FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer
Read more
Press Release
Sep 04 2024
FORE Biotherapeutics to Participate in Upcoming Investor Conferences
Read more
Press Release
Jun 06 2024
FORE Biotherapeutics to Present at the 2024 Goldman Sachs 45th Annual Global Healthcare Conference
Read more
Press Release
May 10 2024
FORE Biotherapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
Read more
Press Release
Apr 11 2024
FORE Biotherapeutics presenting at Stifel 2024 Virtual Targeted Oncology Forum
Read more
Press Release
Apr 09 2024
FORE Biotherapeutics announces new nonclinical data highlighting the differentiation of plixorafenib in combination with MEK inhibition at #AACR24
Read more
Press Release
Feb 29 2024
FORE Biotherapeutics Names William R. Hinshaw as Chief Executive Officer
Read more
Press Release
Feb 01 2024
FORE Biotherapeutics to Participate in Upcoming Investor Conferences
Read more
Press Release
Dec 07 2023
FORE Biotherapeutics to Present at the 2023 RBC Capital Markets Private Company Conference
Read more
Press Release
Nov 17 2023
FORE Biotherapeutics Announces Oral Presentation at SNO 2023 Reporting Updated Phase 1/2a Results for Plixorafenib in BRAF V600 Advanced Solid Tumors, Including Novel Data for Patients with BRAF V600 Primary CNS Tumors
Read more